CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
CytoDyn Inc. (OTCQB: CYDY) has appointed Dr. Max Lataillade as Senior Vice President and Head of Clinical Development. Dr. Lataillade, with over 20 years of research experience, will lead the company's global R&D strategy and oversee end-to-end R&D activities. He previously served as Vice President at ViiV Healthcare and Bristol-Myers Squibb, specializing in HIV research. Dr. Lataillade is also an assistant clinical professor at Yale University School of Medicine.
CytoDyn's CEO, Dr. Jacob Lalezari, expressed enthusiasm about the appointment, citing Dr. Lataillade's industry accomplishments and skillset as valuable assets for progressing the company's development pipeline. Dr. Lataillade aims to leverage his experience to pursue strategic development opportunities and advance CytoDyn's clinical pipeline, particularly focusing on the development of leronlimab, a CCR5 antagonist with potential for multiple therapeutic indications.
CytoDyn Inc. (OTCQB: CYDY) ha nominato Dr. Max Lataillade come Vice Presidente Senior e Responsabile dello Sviluppo Clinico. Il Dr. Lataillade, con oltre 20 anni di esperienza nella ricerca, guiderà la strategia globale di R&D dell'azienda e supervisionerà le attività di R&D dall'inizio alla fine. In precedenza ha ricoperto il ruolo di Vice Presidente presso ViiV Healthcare e Bristol-Myers Squibb, specializzandosi nella ricerca sull'HIV. Il Dr. Lataillade è anche professore clinico associato presso la Yale University School of Medicine.
Il CEO di CytoDyn, Dr. Jacob Lalezari, ha espresso entusiasmo per la nomina, sottolineando i successi e le competenze del Dr. Lataillade come risorse preziose per far avanzare il pipeline di sviluppo dell'azienda. Il Dr. Lataillade punta a sfruttare la sua esperienza per perseguire opportunità di sviluppo strategico e far progredire il pipeline clinico di CytoDyn, concentrandosi in particolare sullo sviluppo di leronlimab, un antagonista CCR5 con potenziale per molteplici indicazioni terapeutiche.
CytoDyn Inc. (OTCQB: CYDY) ha nombrado al Dr. Max Lataillade como Vicepresidente Senior y Jefe de Desarrollo Clínico. El Dr. Lataillade, con más de 20 años de experiencia en investigación, liderará la estrategia global de I+D de la empresa y supervisará las actividades de I+D de principio a fin. Anteriormente, ocupó el cargo de Vicepresidente en ViiV Healthcare y Bristol-Myers Squibb, especializándose en la investigación del VIH. El Dr. Lataillade también es profesor clínico asociado en la Facultad de Medicina de la Universidad de Yale.
El CEO de CytoDyn, Dr. Jacob Lalezari, expresó su entusiasmo por el nombramiento, citando los logros y habilidades del Dr. Lataillade como activos valiosos para avanzar en la cartera de desarrollo de la empresa. El Dr. Lataillade tiene la intención de aprovechar su experiencia para buscar oportunidades de desarrollo estratégico y avanzar en la cartera clínica de CytoDyn, centrándose especialmente en el desarrollo de leronlimab, un antagonista CCR5 con potencial para múltiples indicaciones terapéuticas.
CytoDyn Inc. (OTCQB: CYDY)는 Dr. Max Lataillade를 수석 부사장 겸 임상 개발 책임자로 임명했습니다. Lataillade 박사는 20년 이상의 연구 경험을 가지고 있으며, 회사의 글로벌 R&D 전략을 이끌고 R&D 활동을 전반적으로 감독할 것입니다. 그는 이전에 ViiV Healthcare와 Bristol-Myers Squibb에서 부사장으로 근무했으며 HIV 연구를 전문으로 했습니다. Lataillade 박사는 또한 예일 대학교 의과대학의 임상 교수로 재직 중입니다.
CytoDyn의 CEO인 Jacob Lalezari 박사는 Lataillade 박사의 성과와 전문성을 회사의 개발 파이프라인을 발전시키는 귀중한 자산으로 평가하며 임명 소식을 반겼습니다. Lataillade 박사는 자신의 경험을 활용하여 전략적인 개발 기회를 추구하고 CytoDyn의 임상 파이프라인을 발전시키는 데 집중할 계획입니다. 특히, 여러 치료 적응증에 대한 잠재력을 가진 CCR5 길항제 leronlimab의 개발에 주력할 것입니다.
CytoDyn Inc. (OTCQB: CYDY) a nommé Dr. Max Lataillade au poste de Vice-Président Senior et Responsable du Développement Clinique. Dr. Lataillade, fort de plus de 20 ans d'expérience en recherche, dirigera la stratégie mondiale de R&D de l'entreprise et supervisera l'ensemble des activités de R&D. Auparavant, il a été Vice-Président chez ViiV Healthcare et Bristol-Myers Squibb, se spécialisant dans la recherche sur le VIH. Dr. Lataillade est également professeur clinique associé à la Yale University School of Medicine.
Le PDG de CytoDyn, Dr. Jacob Lalezari, a exprimé son enthousiasme pour cette nomination, soulignant les succès et les compétences du Dr. Lataillade comme des atouts précieux pour faire avancer le pipeline de développement de l'entreprise. Dr. Lataillade a l'intention de tirer parti de son expérience pour rechercher des opportunités de développement stratégique et faire progresser le pipeline clinique de CytoDyn, en mettant particulièrement l'accent sur le développement de leronlimab, un antagoniste CCR5 présentant un potentiel pour diverses indications thérapeutiques.
CytoDyn Inc. (OTCQB: CYDY) hat Dr. Max Lataillade zum Senior Vice President und Leiter der klinischen Entwicklung ernannt. Dr. Lataillade, der über 20 Jahre Forschungserfahrung verfügt, wird die globale F&E-Strategie des Unternehmens leiten und die F&E-Aktivitäten von Anfang bis Ende überwachen. Zuvor war er als Vice President bei ViiV Healthcare und Bristol-Myers Squibb tätig, wo er sich auf HIV-Forschung spezialisiert hat. Dr. Lataillade ist auch Assistenzprofessor für klinische Medizin an der Yale University School of Medicine.
Der CEO von CytoDyn, Dr. Jacob Lalezari, äußerte sich begeistert über die Ernennung und hob die Erfolge und Fähigkeiten von Dr. Lataillade hervor, die wertvolle Vermögenswerte zur Weiterentwicklung des Unternehmens darstellen. Dr. Lataillade beabsichtigt, seine Erfahrung zu nutzen, um strategische Entwicklungsmöglichkeiten zu verfolgen und die klinische Pipeline von CytoDyn voranzutreiben, insbesondere mit Blick auf die Entwicklung von leronlimab, einem CCR5-Antagonisten mit Potenzial für mehrere therapeutische Indikationen.
- Appointment of experienced industry professional Dr. Max Lataillade as SVP and Head of Clinical Development
- Dr. Lataillade brings over 20 years of research experience, including leadership roles at ViiV Healthcare and Bristol-Myers Squibb
- Potential for advancing the development of leronlimab, a CCR5 antagonist with multiple therapeutic indications
- None.
VANCOUVER, Washington, Oct. 08, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Max Lataillade, DO, MPH, has been appointed as Senior Vice President and Head of Clinical Development. Under his consulting agreement, Dr. Lataillade will lead the Company’s global research and development strategy and oversee end-to-end R&D activities to advance the Company’s clinical development pipeline.
Dr. Lataillade brings over two decades of in-depth research experience to the CytoDyn team, with robust expertise investigating novel drug products and therapies. He most recently served as Vice President, Head of Early Development and Global Research Strategy at ViiV Healthcare, where he oversaw its novel HIV oral and long-acting pipeline. Prior to that, he was Vice President and Head of Global Development for HIV at Bristol-Myers Squibb, having joined the global clinical research group in 2007 as an infectious disease and HIV specialist. Dr. Lataillade is also currently an assistant clinical professor and teaching attending at the Yale University School of Medicine.
“I am deeply enthusiastic to welcome Dr. Lataillade to the CytoDyn team. I have had several opportunities to collaborate with him over the past ten years and I believe his accomplishments in the industry and his skillset will help us progress our development pipeline,” said Dr. Jacob Lalezari, CEO. “I look forward to working with Dr. Lataillade to capitalize on both early and continued clinical results, and to help drive further success for the Company.”
Dr. Lataillade added, “I am ready to leverage my experience and background to pursue strategic development opportunities and advance CytoDyn’s clinical pipeline. By further developing leronlimab, I believe CytoDyn is poised to provide material benefits to patients suffering from a number of serious conditions. I look forward to working with Dr. Lalezari to drive the Company’s clinical development.”
Dr. Lataillade obtained his medical degree from the University of Medicine and Dentistry of New Jersey, completed his medical residency training at Temple University and Crozer-Chester Medical Center in Philadelphia in 2004, and finished his fellowship in Infectious Diseases and HIV at Yale University School of Medicine in 2007. He remains a practicing physician with a diversified practice.
About CytoDyn
CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. Leronlimab is being studied for oncology and inflammation, as well as other potential indications, including but not limited to HIV and MASH.
Note Regarding Forward-Looking Statements
This news release contains forward-looking statements relating to, among other things, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2024, including the section captioned “Forward-Looking Statements” and in Item 1A. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Media Contacts
CytoDyn
Riyaz Lalani
Gagnier Communications
CytoDyn@gagnierfc.com
FAQ
Who did CytoDyn (CYDY) appoint as Senior Vice President and Head of Clinical Development?
What is Dr. Max Lataillade's background before joining CytoDyn (CYDY)?
What will be Dr. Max Lataillade's role at CytoDyn (CYDY)?
What is the main product CytoDyn (CYDY) is developing?
